Phase 3 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been newly diagnosed with a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL) that tests positive for a protein called CD-22 (but not the "Burkitt type" of ALL)
- You are between 18 and 39 years old
- You are reasonably well and able to carry out daily activities, rated on a standard scale from 0 (fully active) to 2 (up and about more than half the day) (confirm with trial site)
- Your liver enzyme levels (AST and ALT) are within an acceptable range, unless your leukemia has spread to the liver
- Your liver's bilirubin level is within an acceptable range, unless your leukemia has spread to the liver
- Your kidneys are working well enough, based on a standard calculation of kidney function
- At a later stage, you have completed the first phase of treatment (called remission induction therapy)
- At a later stage, your bone marrow shows 25% or fewer abnormal blast cells remaining after initial treatment
- At a later stage, your blood counts (white blood cells and platelets) have recovered to acceptable levels after initial treatment
Who may not be able to join:
- You have a specific genetic change in your leukemia cells known as the BCR-ABL fusion or the Philadelphia chromosome (t(9;22)) — these patients may be directed to a different study
- You have already received treatment for ALL, other than a short course (7 days or fewer) of steroids or hydroxyurea, or a single dose of a drug injected into the spinal fluid (note: long-term steroids taken for unrelated conditions such as asthma or lupus are acceptable)
- You have previously received treatment for acute leukemia, beyond emergency treatments for specific life-threatening complications
- You are currently pregnant or breastfeeding, as the drugs used in this trial can harm a developing baby; women who could become pregnant must have a negative pregnancy test within 8 days before joining
- You have Down syndrome, as the treatment may cause too many serious side effects in this group
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: daniel_deangelo@dfci.harvard.edu J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute
Phone: 617-632-2645
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Event-free survival (EFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.